Prescription Patterns of Antidiabetic and Cardiovascular Preventive Medications in Community-dwelling Older Adults with Type 2 Diabetes Mellitus: a Cross-sectional Study

Overview

Journal J Geriatr Cardiol

Specialty Geriatrics

Date 2024 Jan 1

PMID 38161340

Authors

Bahia Chahine

Farah Al Souheil

Venise Hanna

Affiliations

Soon will be listed here.

Abstract

Objective: To describe trends in antidiabetics drug prescription patterns in community-dwelling older adults with type 2 diabetes mellitus (T2DM) and to evaluate the use of cardiovascular preventive medications among those diagnosed with atherosclerotic cardiovascular disease (ASCVD).

Methods: This cross-sectional, face-to-face interview study that comprised community-dwelling older adults (≥ 65 years) diagnosed with T2DM. The study questionnaire included the patients' demographics, clinical data, and current medication use. Patients with established ASCVD were further classified into low (i.e., not receiving evidence-based therapy or only one) and high (i.e., receiving at least two evidence-based therapies) composite score groups. Bivariate analysis followed by multivariable logistic regression analysis were performed to evaluate the demographic/clinical characteristics associated with the use of antidiabetic monotherapy/polytherapy and evidence-based pharmacotherapy.

Results: A total of 500 older adults were enrolled. The mean age of included participants was 73 ± 7 years, 310 participants (62%) were males, and 385 participants (77.0%) had established ASCVD. Antidiabetic monotherapy was reported in 251 participants (50.2%), with metformin followed by sulfonylureas being the most commonly prescribed drugs as monotherapy. The results of the multivariable analysis showed that age [odds ratio (OR) = 0.89, 95% CI: 0.85-0.94, < 0.001], obesity (OR = 4.18, 95% CI: 1.63-10.36, = 0.003), hypertension (OR = 4.2, 95% CI: 1.22-7.66, = 0.04), and dyslipidemia (OR = 4.1, 95% CI: 1.28-8.30, = 0.01), were significantly associated with the prescription of cardiovascular preventive medications.

Conclusions: Only one in twenty-one participant with T2DM and ASCVD collectively received three guideline-recommended therapies, indicating a deficiency of utilization of cardiovascular preventive drugs.

References

. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S144-S174. DOI: 10.2337/dc22-S010. View

Hamid A, Vaduganathan M, Oshunbade A, Ayyalasomayajula K, Kalogeropoulos A, Lien L . Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center. J Cardiovasc Pharmacol. 2020; 76(3):313-320. DOI: 10.1097/FJC.0000000000000864. View

Nam S, Chesla C, Stotts N, Kroon L, Janson S . Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract. 2011; 93(1):1-9. DOI: 10.1016/j.diabres.2011.02.002. View

Cerf M . Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013; 4:37. PMC: 3608918. DOI: 10.3389/fendo.2013.00037. View

Kramer C, Zinman B . Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. Annu Rev Med. 2018; 70:323-334. DOI: 10.1146/annurev-med-042017-094221. View

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

. 13. Older Adults: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S195-S207. PMC: 8935395. DOI: 10.2337/dc22-S013. View

Funck K, Knudsen J, Hansen T, Thomsen R, Grove E . Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019. Diabetes Obes Metab. 2020; 23(2):520-529. PMC: 7839758. DOI: 10.1111/dom.14245. View

Liu J, Ge L, Li J, Li X, Feng F, Zhang H . [ACEI/ARB use among high risk patients with coronary heart disease in China: a cross-sectional study]. Zhonghua Xin Xue Guan Bing Za Zhi. 2013; 41(1):18-22. View

10.

Nelson A, OBrien E, Kaltenbach L, Green J, Lopes R, Morse C . Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2022; 5(2):e2148030. PMC: 8855234. DOI: 10.1001/jamanetworkopen.2021.48030. View

11.

Costa J, Borges M, David C, Vaz Carneiro A . Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006; 332(7550):1115-24. PMC: 1459619. DOI: 10.1136/bmj.38793.468449.AE. View

12.

Meier M, Hummel M . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc Health Risk Manag. 2009; 5:859-71. PMC: 2773745. DOI: 10.2147/vhrm.s4808. View

13.

Wade D, Vergis E . The Short Orientation-Memory-Concentration Test: a study of its reliability and validity. Clin Rehabil. 1999; 13(2):164-70. DOI: 10.1191/026921599673848768. View

14.

Lee S, Oh J, Park J, Choi S, Wee J . Differences in youngest-old, middle-old, and oldest-old patients who visit the emergency department. Clin Exp Emerg Med. 2018; 5(4):249-255. PMC: 6301865. DOI: 10.15441/ceem.17.261. View

15.

Sleight P . The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst. 2002; 1(1):18-20. DOI: 10.3317/jraas.2000.002. View

16.

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

17.

Gregg E, Cheng Y, Saydah S, Cowie C, Garfield S, Geiss L . Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care. 2012; 35(6):1252-7. PMC: 3357247. DOI: 10.2337/dc11-1162. View

18.

Mannucci E . [Results of the LEADER study: current evidence and perspectives in research]. G Ital Cardiol (Rome). 2017; 17(12 Suppl 2):28S-31. DOI: 10.1714/2616.26913. View

19.

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

20.

Gomez-Huelgas R, Gonzalez D, Abadias M, Puig J, Ena J . Prescription patterns of antihyperglycemic drugs in elderly patients in Spain: A national cross-sectional study. Rev Clin Esp (Barc). 2019; 220(3):155-161. DOI: 10.1016/j.rce.2019.05.011. View